Corbin R. Azucenas

Corbin R. Azucenas

Auto-generated profile, based on publicly available information

Corbin R. Azucenas

Cincinnati Children's Hospital Medical Center, Cincinnati, OH

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2023 in American Journal of Physiology-Cell Physiology
Verified
Journal Article
Closed access
CACorbin R. Azucenas
Corbin R. Azucenas
TRT. Alex Ruwe
T. Alex Ruwe
JBJohn P. Bonamer
John P. Bonamer
BQBo Qiao
Bo Qiao
TGTomas Ganz
Tomas Ganz
BMBryan Mackenzie
Bryan Mackenzie
Ferroportin (Fpn)—expressed at the plasma membrane of macrophages, enterocytes, and hepatocytes—mediates the transfer of cellular iron into the blood plasma. Under the control of the iron-regulatory hormone hepcidin, Fpn serves a critical role in systemic iron homeostasis. Although we have previously characterized human Fpn, a great deal of research in iron homeostasis and disorders uses mouse models. By way of example, the flatiron mouse, a model of classical ferroportin disease, bears the mutation H32R in Fpn and is characterized by systemic iron deficiency and macrophage iron retention. The flatiron mouse also appears to exhibit a manganese phenotype, raising the possibility that mouse Fpn serves a role in manganese metabolism. At odds with this observation, we have found that human Fpn does not transport manganese, so we considered the possibility that a species difference could explain this discrepancy. We tested the hypothesis that mouse but not human Fpn can transport manganese and performed a comparative analysis of mouse and human Fpn. We examined the functional properties of human Fpn, mouse Fpn, and mutant mouse Fpn by using radiotracer assays in RNA-injected Xenopus oocytes. We found that neither mouse nor human Fpn transports manganese. Mouse and human Fpn share identical properties with respect to substrate profile, calcium dependence, optimal pH, and hepcidin sensitivity. We have also demonstrated that Fpn is not an ATPase pump. Our findings validate the use of mouse models of ferroportin function in iron homeostasis and disease.

15 November 2020 in FEBS Open Bio
Verified
Journal Article
Open access
PDF file
CDChandrika N. Deshpande
Chandrika N. Deshpande
CACorbin R. Azucenas
Corbin R. Azucenas
BQBo Qiao
Bo Qiao
NNNorimichi Nomura
Norimichi Nomura
VXVicky Xin
Vicky Xin
MJMika Jormakka
Mika Jormakka
Ferroportin (Fpn) is an essential mammalian iron transporter that is negatively regulated by the hormone hepcidin. Our current molecular understanding of Fpn‐mediated iron efflux and regulation is limited due to a lack of biochemical, biophysical, and high‐resolution structural studies. A critical step towards understanding the transport mechanism of Fpn is to obtain sufficient quantities of pure and stable protein for downstream studies. As such, we detail here an expression and purification protocol for mouse Fpn yielding milligram quantities of pure protein. We have generated deletion constructs exhibiting enhanced thermal stability and which retained iron‐transport activity and hepcidin responsiveness, providing a platform for further biophysical studies of Fpn.

18 April 2020 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
CACorbin R. Azucenas
Corbin R. Azucenas
ASAli Shawki
Ali Shawki
BLBrandon L. Logeman
Brandon L. Logeman
ENEric J. Niespodzany
Eric J. Niespodzany
JDJustin L. Dunham
Justin L. Dunham
BMBryan Mackenzie
Bryan Mackenzie
Divalent metal‐ion transporter‐1 (DMT1) and the high‐affinity copper transporter‐1 (CTR1) play essential roles in the intestinal absorption of iron and copper respectively. Both transporters are potential therapeutic targets in disorders of metal metabolism. Disagreement remains over whether the metal‐ion specificities of the two transporters overlap. For example, others have concluded that DMT1 transports Cu + and CTR1 transports Fe 2+ based on the results of shRNA knockdown of gene expression in Caco‐2 cells [Espinoza A et al (2012) Biol Trace Elem Res 146, 281]. Since these observations contradicted our published data regarding the substrate profile of DMT1 in vitro [Illing AC et al (2012) J Biol Chem 287, 30485] and in vivo [Shawki A et al (2015) Am J Physiol Gastrointest Physiol 309, G635] or of CTR1 in vitro [Lee J et al (2002) J Biol Chem 277, 4380], we have re‐examined metal‐ion transporter substrate profiles. We tested the hypothesis that DMT1 can transport copper and that CTR1 can transport iron by using radiotracer assays and the voltage clamp in RNA‐injected oocytes expressing human DMT1 or CTR1. Expression of CTR1 in oocytes stimulated up to 20‐fold the uptake of 2 μM 64 Cu + (pH 5.5) but did not stimulate the uptake of 64 Cu 2+ or 55 Fe 2+ . Expression of DMT1 in oocytes stimulated 80‐fold the uptake of 2 μM 55 Fe 2+ (pH 6.0) but transport of 64 Cu + or 64 Cu 2+ did not differ from that in control oocytes. We found that Cu + inhibited DMT1‐mediated 55 Fe 2+ uptake in a competitive fashion ( K i ≈ 58 μM). In DMT1‐expressing oocytes, Cu + evoked inward currents; however, such currents were also observed in control oocytes and their I / V relationships did not resemble those for DMT1 substrates Fe 2+ and Cd 2+ . Addition of Fe 2+ or Cd 2+ abolished the presteady‐state (transient) currents observed in the absence of metal ion whereas addition of Cu + or Cu 2+ did not. We found, however, that Cu 2+ accelerated the decay of the transient currents. We conclude that (1) whereas Cu + and Cu 2+ are capable of interacting with DMT1, neither are transported substrates; and (2) CTR1 mediates transport of Cu + but not of Cu 2+ or Fe 2+ . We therefore find no evidence of overlapping metal‐ion specificities in DMT1 and CTR1. Support or Funding Information: PHS grants R01‐DK080047, R01‐DK107309, R01‐DK074192, and R25‐HL115473; and the American Physiological Society

2 November 2023 in Blood
Verified
Journal Article
Open access
CACorbin R Azucenas
Corbin R Azucenas
MSMaria Stewart
Maria Stewart
AVAikaterini Voulgaridou
Aikaterini Voulgaridou
KSKatie Seu
Katie Seu
TKTheodosia Kalfa
Theodosia Kalfa
Disclosures. Kalfa:Agios Pharmaceuticals, Inc.: Consultancy, Research Funding; Forma/Novo Nordisk: Consultancy, Research Funding.Figure 1